William Blair Updates Focus List: Oracle Added, Meta Removed
0xBroomberg
William Blair's July update adds 14 stocks and removes 24 from its Analyst Conviction List — Oracle and American Express headline the additions, while Meta and 21 others exit on automatic six-month expiry, signaling a fresh Wall Street bet on AI infrastructure and consumer resilience.
Why were Oracle and American Express added?
Oracle's case rests on AI infrastructure: hyperscaler cloud commitments have pushed remaining performance obligations — contracts signed but not yet recognized as revenue — to a record high. This means → revenue visibility for the next several quarters is unusually strong.
American Express brings multiple growth levers: rising retention among younger cardholders, plus upside in experiential spending and dining. William Blair sees these combining to deliver mid-teens EPS growth.
In plain terms = one bet is on "the pick-and-shovel supplier of the AI era," the other on "the consumer upgrade still has runway."
What themes do the other additions represent?
Dynatrace (DT): accelerating demand for AI-driven observability — tools that let enterprises monitor software performance in real time — with net-new annual recurring revenue picking up and margins strong.
ServiceTitan (TTAN) was selected for sustained growth plus improving profitability; Comfort Systems USA (FIX) is a data-center build-out play, with William Blair particularly bullish on its Texas footprint and potential backlog upside.
Ecolab (ECL) is expanding margins through pricing power, with faster organic growth expected after integrating acquisitions; Boot Barn (BOOT) was added because valuation and fashion risk are already priced in. This means → downside is limited, while upside optionality has opened up.
Which biotech names made the cut?
Genmab (GMAB) has multiple clinical data readouts — trial results set to be published — in the second half; William Blair is positioning ahead of those catalysts.
Silence Therapeutics (SLN) and Tyra Biosciences (TYRA) were likewise added for upcoming clinical catalysts.
LifeStance Health (LFST) targets the behavioral-health space, with growth driven by a hybrid in-person and virtual care model.
What happened to the 24 stocks removed?
22 were automatic expirations — the Conviction List carries a six-month clock, and names not renewed simply roll off. These include Meta (META), Arista Networks (ANET), Guidewire (GWRE), Rubrik (RBRK), and financials like LPL Financial (LPLA).
In plain terms = most removals are not downgrades — the six-month window closed and the analyst did not re-up.
The two active removals: Axsome Therapeutics (AXSM) was taken off after the FDA approved its drug Auvelity for Alzheimer's-related agitation — the stock gained roughly 48% relative to the S&P 500 since its April addition, delivering on the thesis. Rollins (ROL) was removed on murkier near-term growth and margin trends, though William Blair says the long-term case still holds.
Among current holdings, who leads and who lags?
Credo Technology (CRDO) tops the board with 109% excess return versus the S&P 500; Twilio (TWLO) follows at 49.1%, and Repligen (RGEN) at 32%.
At the bottom: Karman Holdings (KRMN) at -52.4%, iRhythm (IRTC) at -31.2%, and Jack Henry (JKHY) at -24.2%.
Newly added names — Oracle, American Express, and the rest — all start at 0%, benchmarked from the day of inclusion. This reflects the Conviction List's nature as a rolling six-month horse race: every entry and exit is a fresh wager.
Content is for reference only, not financial advice.